Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen executives laid out the case for the heart failure candidate ivabradine, which will serve as a foundation for the launch of the company’s highly anticipated PCSK9 inhibitor, during a presentation at AHA. The company also presented the first 52-week data on evolocumab.
You may also be interested in...
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends
In shifting away from specific targets and non-statin add-on therapies, new ACC/AHA cholesterol guidelines support treatment of people at relatively low risk for events and more intensive therapy for those at higher risk.
Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.